AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Clear Cell Renal Cell Carcinoma Clinical Trial

— AUR87A  

Official title:

AURORAX-0087A: Glycosaminoglycan Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic Clear Cell Renal Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04006405
• Other study ID #: ECD-AUR87A001
• Status: Recruiting
• Start date: January 10, 2020
• Est. completion date: February 2025

Study information

• Verified date: May 2023
• Source: Elypta
• Contact: Saeed Dabestani
• Phone: +46(0)707198567
• Email: saeed.dabestani[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

AUR87A is an observational prospective multicenter diagnostics test cohort study for detection of renal cell carcinoma recurrence as determined by the reference standard, which is imaging using computed tomography (CT) of the chest and abdomen at defined intervals after primary surgery.

Description:

Non-metastatic clear cell renal cell carcinoma (ccRCC) recur in ~20% of cases within 5 years after radical surgery. Current postoperative follow-up protocols, being schematic and at best based on risk of recurrence scores, are sub-optimal for early detection of recurrences which could potentially be available for curative management. Blood and urine collected glycosaminoglycans (GAGs) are promising novel class of biomarkers from which a new diagnostic test based on so called GAG scores has been developed. GAG scores have accurately distinguished localized/locally-advanced and advanced RCC from healthy subjects. AUR87A features an adaptive design. The primary endpoint analysis is conducted when 30 events (i.e. recurrences) are reached - expected at 140 patients with a minimum follow-up of 12 months (cohort 1). An interim analysis at 15 events is conducted to verify whether the sensitivity and specificity estimates are in line with the study assumptions. In case of futility, the GAG scores formulations and/or cut-offs are optimized based on data from cohort 1. The primary endpoints are then validated on a second independent cohort, powered depending on the results from cohort 1. This second cohort is estimated in 140 patients (cohort 2). In case of non-futility, cohort 2 may be used as external validation. AUR87A will prospectively enroll an estimated 280 non-metastatic ccRCC patients curatively treated with surgery (partial or radical nephrectomy). Patients are followed-up longitudinally using GAG scores in blood and urine every 3 months after surgery, alongside the current standard follow-up protocol, i.e. imaging, as reference standard. The hypothesis of AUR87A is that postoperative increase of the GAG scores, so called "GAG recurrence ", can predict or detect recurrence at an earlier time-point compared to the reference standard, referred to as "radiological recurrence", and thereby improve the clinical utility of current follow-up protocols.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 280
• Est. completion date: February 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Pre-screening inclusion criteria

• Size of primary tumor >4cm (>cT1a) in greatest dimension on pre-operative abdominal CT-scan
• Size of primary tumor =4cm is allowed if pre-operative abdominal CT-scan shows suspected RCCs with radiological sign of venous tumor thrombus (renal vein or caval).
• Pre-operative CT-scan of chest and abdomen show no signs of metastatic disease
• Localized and biopsy proven clear cell RCC (ccRCC) under active surveillance which at timepoint of study recruitment, opted for surgery because of growth rate of primary tumor to a size > 4cm
• Elected for curative intent surgery for RCC Final screening inclusion criteria
• Any gender being 18 years or older at timepoint of final inclusion
• In postoperative pathology report shown to be ccRCC subtype according to 8th Edition of the American Joint Committee on Cancer (AJCC)
• Leibovich points (LP) =5 according to Leibovich score system (2003)
• If pathology report shows multiple subtypes in same tumor, as long as the majority of tumor is ccRCC (>50%), participant can be included Exclusion Criteria: Pre-screening exclusion criteria
• TNM-stage T(any) N(any) M1 according to AJCC, i.e. metastatic disease at diagnosis
• Absence of preoperative chest imaging (chest CT) within 60 days prior to primary surgery
• Previous history of curatively treated for other cancers, still not deemed fully cured and participant still under surveillance for said cancer
• Participants offered active surveillance for RCC instead of curative intent surgery
• Participants offered any type of thermal ablation treatment instead of surgery, i.e. LP cannot be assessed Final screening exclusion criteria
• Participants with AJCC cN0 status at preoperative imaging in whom a clinically suspicious regional lymph-node metastases (enlarged lymph node(s)) is noted during primary surgery, but who subsequently do not undergo any lymph node dissection. (Note: participants with cN0 status at pre-operative imaging and no clinical signs of regional lymph node metastases during primary surgery can still be included irrespective of lymph node dissection having been performed, i.e. being pN0 or pN1 if it is performed or pNx if it is not performed)
• Participants with AJCC cN1 status at pre-operative imaging in which lymph node dissection is not performed (i.e. pNx).
• Elected for any adjuvant therapy (i.e. systemic therapy) outside or within any clinical study
• Non-clear cell RCC histology or benign tumor (i.e. oncocytoma and angiomyolipoma, which are the most common benign types, but also any other rare types of benign renal tumors) after pathological analysis
• Any hereditary form of RCC (e.g. Von Hippel-Lindau, Birt-Hogg-Dubé, Hereditary Papillary RCC)
• RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
• Previous history of curatively treated for RCC with a suspected de novo RCC in the remaining kidney tissue
• Prior or current use of instillation therapy with hyaluronic acid and/or chondroitin sulfate (HA-CS).
• Use of heparin, including low molecular weight heparin (e.g. Enoxaparin, Dalteparin, Tinzaparin) for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively =4 weeks will be allowed.
• Patients who were not radically operated during primary surgery with the exception of histological positive surgical margin in participants who have undergone partial nephrectomy.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Clear Cell Renal Cell Carcinoma
• Recurrence

Intervention

Diagnostic Test:
• GAG score
blood and urine samples to determine GAG scores

Locations

Country	Name	City	State
Canada	Prostate Cancer Centre	Calgary
Denmark	Aarhus University Hospital	Aarhus
Denmark	Odense University Hospital	Odense
Denmark	Zealand University Hospital	Roskilde
Finland	Helsinki University Central Hospital	Helsinki
France	Hôpital Henri Mondor	Créteil
Italy	AOU San Orsola Malpighi	Bologna
Italy	Careggi University Hospital	Florence
Italy	San Raffaele Hospital	Milano
Italy	AOU San Luigi Gonzaga	Orbassano
Italy	Istituto Nazionale Tumori Regina Elena	Roma
Italy	AOU Integrata Verona	Verona
Portugal	Hospital da Luz Coimbra	Coimbra
Spain	Hospital Universitario Cabueñes	Gijón
Sweden	Sahlgrenska University Hospital	Gothenburg
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	Western General Hospital	Edinburgh
United Kingdom	Frimley Park Hospital	Frimley
United Kingdom	Guys & St Thomas Hospital	London
United Kingdom	Royal Free Hospital	London
United Kingdom	Norfolk & Norwich University Hospital	Norwich
United Kingdom	Royal Berkshire Hospital	Reading
United Kingdom	Salford Royal NHS Foundation Trust	Salford
United States	Emory University School of Medicine	Atlanta	Georgia
United States	MD Anderson Cancer Center	Houston	Texas
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Elypta

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  Finland,  France,  Italy,  Portugal,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity of GAG recurrence	Sensitivity and specificity of GAG recurrence to LP=5 ccRCC radiological or histologically verified recurrence with a minimum follow-up time of 12 months	minimum follow-up of 12 months
Secondary	Absolute and relative risk increase (ARI/RRI) of radiological recurrence	Absolute and relative risk increase (ARI/RRI) of radiological recurrence in patients with GAG recurrence versus no GAG recurrence	within 6 months since last GAG score evaluation
Secondary	Recurrence-free survival (RFS)	Recurrence-free survival (RFS) in the LP=5 ccRCC for GAG recurrence vs. no GAG recurrence with a minimum follow-up time of 12 months	minimum follow-up of 12 months
Secondary	Positive and negative predictive value (PPV/NPV) of GAG recurrence	Positive and negative predictive value (PPV/NPV) of GAG recurrence to LP =5 ccRCC radiological recurrence	minimum follow-up of 12 months
Secondary	Area under the receiver-operating-characteristic curve (AUC) of GAG scores	Area under the receiver-operating-characteristic curve (AUC) of GAG scores to LP =5 ccRCC radiological recurrence	minimum follow-up of 12 months
Secondary	RFS, overall survival (OS) and cancer specific survival (CSS)	RFS, overall survival (OS) and cancer specific survival (CSS) in patients with GAG recurrence versus no GAG recurrence	follow-up time of 2 years and 5 years respectively after primary surgery
Secondary	Concordance-index (C-index) of preoperative GAG scores	Concordance-index (C-index) of preoperative GAG scores versus risk nomograms for RFS and for CSS	follow-up time of 2 years and 5 years respectively after primary surgery
Secondary	Lead-time GAG vs. radiological recurrence among true positives	Lead-time GAG vs. radiological recurrence among true positives	minimum follow-up of 12 months

External Links

•   Official website for AURORAX-87A